Document is current
Any future updates will be listed below
-
Authors
Fares, Andrew
Wickens, Christine M.
Mann, Robert E.
Di Ciano, Patricia
Wright, Madison
Matheson, Justin
Hasan, Omer S. M.
Rehm, Jurgen
George, Tony P.
Samokhvalov, Andriy V.
Shuper, Paul A.
Huestis, Marilyn A.
Stoduto, Gina
Brown, Timothy
Stefan, Cristiana
Rubin-Kahana, Dafna Sara
Le Foll, Bernard
Brands, Bruna
-
Funding
Funding for this research was provided by:
Canadian Institutes of Health Research (MOP-142196)
- License Information
-
More Information
Article History
Received: 21 September 2020
Accepted: 21 January 2021
First Online: 5 February 2021
Declarations
:
: Dr. Le Foll has obtained funding from Pfizer (GRAND Awards, including salary support) for investigator-initiated projects. Dr. Le Foll has some in-kind donation of cannabis product from Aurora and medication donation from Pfizer and Bioprojet and was provided a coil for TMS study from Brainsway. Dr. Le Foll has obtained industry funding from Canopy (through research grants handled by CAMH or University of Toronto), Bioprojet, ACS, and Alkermes. Dr. Le Foll has received in kind donations of nabiximols from GW Pharma for past studies funded by CIHR and NIH. Dr. George has partial salary support from NIDA (R21-DA-043949) and is a consultant to Frutarom. Dr. Huestis was a consultant to Canopy Health Innovations on medical cannabis study design, is a Science and Policy Advisor, PinneyAssociates, and President of Huestis & Smith Toxicology, LLC.
: The funders had no role in the design of the trial, collection or analysis of data, or preparation of manuscripts.
